Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9493
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, X. | - |
dc.contributor.author | Pan, H. | - |
dc.contributor.author | Cui, J. | - |
dc.contributor.author | Chen, X. | - |
dc.contributor.author | Yoon, Won-Hee | - |
dc.contributor.author | Carlino, Matteo S. | - |
dc.contributor.author | Li, X. | - |
dc.contributor.author | Li, H. | - |
dc.contributor.author | Zhang, J. | - |
dc.contributor.author | Sun, J. | - |
dc.contributor.author | Guo, J. | - |
dc.contributor.author | . | - |
dc.date.accessioned | 2024-04-23T04:29:54Z | - |
dc.date.available | 2024-04-23T04:29:54Z | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | Immunotherapy 16(4):243-256, 2024 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9493 | - |
dc.description.abstract | AIM: Investigate TKI sitravatinib plus anti-PD-1 antibody tislelizumab in patients with unresectable/advanced/metastatic melanoma with disease progression on/after prior first-line anti-PD-(L)1 monotherapy. METHODS: Open-label, multicenter, multicohort study (NCT03666143). Patients in the melanoma cohort (N = 25) received sitravatinib once daily plus tislelizumab every 3 weeks. The primary end point was safety and tolerability. RESULTS: Treatment-emergent adverse events (TEAEs) occurred in all patients, with >=grade 3 TEAEs in 52.0%. Most TEAEs were mild-or-moderate in severity, none were fatal, and few patients discontinued treatment owing to TEAEs (12.0%). OBJECTIVE response rate was 36.0% (95% CI: 18.0-57.5). Median progression-free survival was 6.7 months (95% CI: 4.1-not estimable). CONCLUSION: Sitravatinib plus tislelizumab had manageable safety/tolerability in patients with anti-PD-(L)1 refractory/resistant unresectable/advanced/metastatic melanoma, with promising antitumor activity. | - |
dc.subject | Oncology | - |
dc.title | SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.2217/imt-2023-0130 | - |
dc.subject.keywords | drug therapy, combination | - |
dc.subject.keywords | immunotherapy | - |
dc.subject.keywords | melanoma | - |
dc.identifier.journaltitle | Immunotherapy | - |
dc.identifier.department | Oncology | - |
dc.contributor.wslhd | Yoon, Won-Hee | - |
dc.contributor.wslhd | Carlino, Matteo S. | - |
dc.type.studyortrial | Multicentre Study | - |
dc.identifier.pmid | 38197138 | - |
dc.identifier.affiliation | Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China | - |
dc.identifier.affiliation | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China | - |
dc.identifier.affiliation | The First Hospital of Jilin University, Changchun, China | - |
dc.identifier.affiliation | Blacktown Cancer and Haematology Centre, Blacktown, NSW, Australia | - |
dc.identifier.affiliation | Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia | - |
dc.identifier.affiliation | BeiGene Co., Ltd., Beijing, China | - |
dc.identifier.affiliation | BeiGene Co., Ltd., Shanghai, China | - |
dc.identifier.facility | Blacktown | - |
dc.identifier.facility | Westmead | - |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.